Safe use of Cogivis and Silenta neuroadaptogens in pediatric practice

M.V. Khaitovych


Over the last decade, the prevalence of autonomic dysfunction in children has significantly increased. Anxiety, insomnia violate the vegetative regulation, cause frequent headaches, blood pressure variability, deterioration of attention, memory, reduce the quality of life of the child and family. We have evaluated the data of evidence-based medicine in the aspect of safe usage of GABA receptor agonists (benzodiazepines, Z-drugs), melatonin and drugs used to treat children with attention deficit hyperactivity disorder (stimulating and non-stimulating), etc. The application of these drugs is often accompanied by side effects, which make it impossible to use them routinely. The alternative is to use combination drugs with synergistic action that minimizes the side effects. The expediency of using Cogivis and Silenta combination drugs for neuroadaptation of children was substantiated.


children; treatment; side effects; Silenta; Cogivis


Khaitovych MV, Оcheretko VV, Misiura OM. The frequency and nature of insomnia in adolescents and their impact on quality of life. In: Proceeding of the XI Congress of Pediatricians of Ukraine. 2015 Oct 7-9; Kyiv, Ukraine. (in Ukrainian).

Khaitovych MV, Potaskalova VS, Misiura OM. Lifestyle and primary headache in schoolchildren. Sotsialna pediatriia i reabilitolohiia. 2017;(11-12):19-24. (In Ukrainian).

Grau K, Plener PL. Pharmacotherapy for children and adolescents with sleep disorders: an overview. Z Kinder Jugendpsychiatr Psychother. 2018 Sep;46(5):393-402. doi: 10.1024/1422-4917/a000562.

Ford ES, Cunningham J, Giles WH, Croft JB. Trends in insomnia and excessive daytime sleepiness among U.S. adults from 2002 to 2012. Sleep Med. 2015 Mar;16(3):372-8. doi: 10.1016/j.sleep.2014.12.008.

Li Y, Starr LR, Wray-Lake L. Insomnia mediates the longitudinal relationship between anxiety and depressive symptoms in a nationally representative sample of adolescents. Depress Anxiety. 2018 Jun;35(6):583-591. doi: 10.1002/da.22764.

Owens JA, Moore M. Insomnia in Infants and Young Children. Pediatr Ann. 2017 Sep 1;46(9):e321-e326. doi: 10.3928/19382359-20170816-02.

Anand S, Tong H, Besag FMC, Chan EW, Cortese S, Wong ICK. Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment. Paediatr Drugs. 2017 Jun;19(3):235-250. doi: 10.1007/s40272-017-0224-6.

Matheson E, Hainer BL. Insomnia: Pharmacologic Therapy. Am Fam Physician. 2017 Jul 1;96(1):29-35.

Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017 Dec;26(6):675-700. doi: 10.1111/jsr.12594.

Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470.

Bruni O, Angriman M. Pediatric insomnia: New insights in clinical assessment and treatment options. Arch Ital Biol. 2015 Jun-Sep;153(2-3):144-56. doi: 10.12871/000398292015239.

Shtrygol SYu, Kortunova TV, Shtrygol DV. Side effects of nootropic drugs. Provіzor. 2003;11. Available from:

Naprieienko OK, Khaitovych MV. Klinichna psykhofarmakolohiia: navchalnyi posibnyk dlia studentiv medychnykh (farmatsevtychnykh) VNZ [Clinical Psychopharmacology: A Manual for Students of Medical (Pharmaceutical) Higher Educational Institutions]. Kyiv; 2016. 136 p.

WHO. International monitoring of adverse reactions to drugs : adverse reaction terminology, 31 December 1992. Available from:

Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors. Drug Saf. 2016 Sep;39(9):847-57. doi: 10.1007/s40264-016-0444-7.

Kurian J, Mathew J, Sowjanya K, et al. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study. Indian J Pediatr. 2016 May;83(5):414-9. doi: 10.1007/s12098-015-2002-1.

Furukawa T, Shimoyama S, Miki Y, et al. Chronic diazepam administration increases the expression of Lcn2 in the CNS. Pharmacol Res Perspect. 2017 Jan 31;5(1):e00283. doi: 10.1002/prp2.283.

Żurowska N, Kałwa A, Rymarczyk K, Habrat B. Recognition of emotional facial expressions in benzodiazepinedependence and detoxification. Cogn Neuropsychiatry. 2018 Mar;23(2):74-87. doi: 10.1080/13546805.2018.1426448.

Revet A, Yrondi A, Montastruc F. Good practices in prescribing benzodiazepines. Presse Med. 2018 Oct;47(10):872-877. doi: 10.1016/j.lpm.2018.10.008.

Gupta MK, Mondkar JA, Hegde D. Paradoxical Reaction to Midazolam in Preterm Neonates: A Case Series. Indian J Crit Care Med. 2018 Apr;22(4):300-302. doi: 10.4103/ijccm.IJCCM_36_17.

McDonagh MS, Holmes R, Hsu F. Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review. J Child Neurol. 2019 Apr;34(5):237-247. doi: 10.1177/0883073818821030.

Clavenna A, Bonati M. Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. Expert Opin Drug Saf. 2017 Dec;16(12):1335-1345. doi: 10.1080/14740338.2017.1389894.

Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990. doi: 10.1002/14651858.CD007990.pub3.

Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One. 2017 Jul 12;12(7):e0180355. doi: 10.1371/journal.pone.0180355.

Frampton JE. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD. Drugs. 2018 Jul;78(10):1025-1036. doi: 10.1007/s40265-018-0936-0.

Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2.

Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):19-28. doi: 10.1089/cap.2017.0053.

Wigal SB, Childress A, Berry SA, et al. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699. doi: 10.1089/cap.2016.0177.

Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018 May 9;5:CD012069. doi: 10.1002/14651858.CD012069.pub2.

Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Aug;27(6):474-482. doi: 10.1089/cap.2017.0084.

Childress AC, Wigal SB, Brams MN, et al. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):306-313. doi: 10.1089/cap.2017.0095.

Maras A, Schroder CM, Malow BA, et al. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2018 Oct 11. doi: 10.1089/cap.2018.0020.

Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL. Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry. 2017 Nov;56(11):948-957.e4. doi: 10.1016/j.jaac.2017.09.414.

Melo G, Dutra KL, Rodrigues Filho R, et al. Association between psychotropic medications and presence of sleep bruxism: A systematic review. J Oral Rehabil. 2018 Jul;45(7):545-554. doi: 10.1111/joor.12633.

Chow ES, Zangeneh-Kazemi A, Akintan O, Chow-Tung E, Eppel A, Boylan K. Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project. J Can Acad Child Adolesc Psychiatry. 2017 Jul;26(2):98-103.

Ripoli C, Pinna AP, Podda F, Zanni R, Tronci MG, Nurchi AM. Second-generation antipsychotic and diabetes mellitus in children and adolescents. Pediatr Med Chir. 2017 Dec 13;39(4):149. doi: 10.4081/pmc.2017.149.

Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the Treatment of Insomnia in Adolescents. J Child Adolesc Psychopharmacol. 2017 Nov;27(9):792-795. doi: 10.1089/cap.2016.0206.

Khaitovych MV. Pharmacological correction of stress-induced autonomic disorders and insomnia in children. Meždunarodnyj nevrologičeskij žurnal. 2018;(102):38-43. doi: 10.22141/2224-0713.8.102.2018.153541.

Kvashnina LV, Maidan IS, Ignatova TB.Possibilities of complex correction of manifestations of school maladaptation in children of elementary school age. Zdorov`e rebenka. 2019;14(2):2-7.

Copyright (c) 2020 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта